A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations-Reference-Cited by-同舟云学术

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

Published:2011-08 Issue:8 Volume:6 Page:1435-1437
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Riely Gregory J.,Johnson Melissa L.,Medina Chanoa,Rizvi Naiyer A.,Miller Vincent A.,Kris Mark G.,Pietanza M. Catherine,Azzoli Christopher G.,Krug Lee M.,Pao William,Ginsberg Michelle S.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference13 articles.

1. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient;Santos;Science,1984

2. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma;Riely;Clin Cancer Res,2008

3. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib;Pao;PLoS Med,2005

4. Are RAS mutations predictive markers of resistance to standard chemotherapy?;Loriot;Nat Rev Clin Oncol,2009

5. Hyperactive Ras in developmental disorders and cancer;Schubbert;Nat Rev Cancer,2007

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Duodenal Fluid Analysis as a Rewarding Approach to Detect Low-Abundance Mutations in Biliopancreatic Cancers;International Journal of Molecular Sciences;2024-08-02

2. Tumor biomarkers for diagnosis, prognosis and targeted therapy;Signal Transduction and Targeted Therapy;2024-05-20

3. Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments;Drugs;2024-04-16

4. Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment;Cancers;2024-03-02

5. Deciphering the role of KRAS gene in oncogenesis: Focus on signaling pathways, genetic alterations in 3’UTR, KRAS specific miRNAs and therapeutic interventions;Critical Reviews in Oncology/Hematology;2024-02